Indole fusion saturated cyclic compounds or derivatives thereof and their applications
Indole-fused saturated cyclic compounds serve as dual inhibitors of xanthine oxidase and uric acid transporter URAT1, addressing the limitations of current drugs by effectively lowering uric acid levels and treating gout and hyperuricemia.
Patent Information
- Application Number
- KR1020267033343
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-23
- Filing Date
- 2025-04-18
- Publication Date
- 2026-11-09
AI Technical Summary
Current drugs for hyperuricemia and gout are inadequate, and there is a need for a dual-target molecule that inhibits both xanthine oxidase and uric acid transporter URAT1 to effectively lower uric acid levels.
Development of indole-fused saturated cyclic compounds or derivatives with structures represented by specific formulas, acting as XOR/URAT1 dual inhibitors, to inhibit both xanthine oxidase and uric acid transporter URAT1.
The compounds exhibit excellent inhibitory activity against both xanthine oxidase and uric acid transporter URAT1, providing a safe and effective uric acid-lowering effect for the prevention and treatment of gout and hyperuricemia.
Smart Images

Figure PCT00107_ABST
Abstract
Description
Technology Field
[0001] The present invention claims priority to a Chinese patent application filed with the National Intellectual Property Administration of China on April 23, 2024, with application number 2024104935740 and title of the invention “Indole-fused saturated cyclic compounds or derivatives thereof and applications thereof,” all contents of said application incorporated by reference into the present invention.
[0002] The present invention relates to the field of medicinal chemistry, specifically to indole-fused saturated cyclic compounds or derivatives thereof and applications thereof. Background Technology
[0003] Uric acid is the end product of purine metabolism in human and non-human primate mammals, generated from xanthine catalyzed by xanthine oxidase. Since humans do not possess uric acid-degrading enzymes, uric acid is ultimately excreted from the body only through the intestines and kidneys. Excessive purine intake due to dietary habits resulting from the popularization of Western-style diets, rapid mass cell death (tumor lysis syndrome), and reduced efficiency of uric acid excretion pathways due to genetic or environmental factors can all lead to hyperuricemia. According to extensive basic and clinical medical data, hyperuricemia itself is an independent high-risk factor regardless of uric acid crystal formation and has been shown to be associated with the pathogenesis of various diseases in the body (e.g., diabetic nephropathy, other chronic kidney diseases, cardiovascular and cerebrovascular diseases). The normal range for human blood uric acid levels is 3 to 6.0 mg / dl (180 to 360 μmol), and the solubility of uric acid is less than 6.5 mg / dl (at 37°C, pH 7.0). If these concentrations are exceeded, crystals may form; lowering the pH or temperature both promote crystal formation. These crystals then deposit in the joints of the extremities or other parts of the body (e.g., blood vessels, kidneys), causing cell damage and inflammation, inflicting severe pain on patients, and severely impacting their quality of life. Hyperuricemia affects 8% of the total population, while gout patients account for 4% of the total population. Gout attacks occur in more than 10% of people aged 60 or older.
[0004] Currently, there are several drugs primarily used to lower uric acid, such as allopurinol or febuxostat, which reduce the production of uric acid by inhibiting xanthine oxidase; benzbromarone, which promotes the excretion of uric acid by interfering with the reabsorption of uric acid in the kidneys; or, for patients with refractory hyperuricemia, the breakdown of uric acid using exogenous recombinant and modified uric acid degrading enzymes (even in combination with immunosuppressants); or some mono-target drugs that target uric acid transporters, such as Lesinurad, which was approved in the U.S. in 2015 but withdrawn from the market in 2019, and Dotinurad, which was launched in Japan.
[0005] Existing drugs and treatments all have certain limitations and fail to meet the clinical needs of the majority of patients with hyperuricemia and gout; therefore, the development of safe and effective novel uric acid-lowering drugs is necessary. From the perspective of mechanism of action and pharmacokinetics, a strategy that simultaneously inhibits the uric acid production pathway (xanthine oxidase) and the uric acid reabsorption pathway (uric acid transporter URAT1, gene name SLC22A12) with a single molecule offers superior advantages over strategies that inhibit each pathway individually. Pfizer developed PF-06743649, a dual-target molecule and XOR / URAT1 dual inhibitor, but clinical trials were discontinued in Phase 1 due to acute kidney injury in a small number of patients. Consequently, there is an urgent need for the development of new dual-target uric acid-lowering drugs that can benefit patients with hyperuricemia and alleviate the burden of national healthcare costs. The problem to be solved
[0006] To solve the above problem, the present invention provides an indole-fused saturated cyclic compound or a derivative thereof, said compound having excellent inhibitory activity against both xanthine oxidase (XOR) and uric acid transporter (URAT1), and as an XOR / URAT1 dual inhibitor, having an excellent uric acid-lowering effect. means of solving the problem
[0007] The present invention includes the following technical solution.
[0008] As an indole fused saturated cyclic compound having a structure represented by formula (I) or formula (II), or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof,
[0009]
[0010] In the above formula, X is -O-, -S-, -CH2-, -NR 2 Selected from;
[0011] Y is -O-, -S-, -NR 2 Selected from;
[0012] m and n are each independently selected from 0, 1, and 2, and m+n=2;
[0013] Z and W are each independently CR 3 Selected from;
[0014] Q is hydrogen, one or more R 4 A C1-C6 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C6 alkoxy group substituted or unsubstituted with , one or more R 4 Selected from substituted or unsubstituted C1-C6 alkylthio groups, halogens, cyano groups, aldehyde groups, carboxyl groups, nitro groups, and hydroxyl groups;
[0015] L is hydrogen, one or more R 4A C1-C6 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C6 alkoxy group substituted or unsubstituted with , one or more R 4 A C1-C6 alkylthio group substituted or unsubstituted with, a halogen, a cyano group, an aldehyde group, a carboxyl group, a nitro group, a hydroxyl group, one or more R 5 A C3-C8 cycloalkyl group substituted or unsubstituted with, one or more R 5 A 3-8 binary heterocyclic ring substituted or unsubstituted with R, one or more R 6 C6-C substituted or unsubstituted 10 Aryl group, one or more R 6 A 5-10-membered heteroaryl group substituted or unsubstituted with, Selected from;
[0016] X 1 , X 2 are independently -O-, -S-, -C(R 1 )2-, -NR 2 Selected from;
[0017] Z 1 , Z 2 and Z 3 CR each independently 3 , selected from N;
[0018] Each R 1 Each is independently selected from hydrogen, C1-C6 alkyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, and halogens;
[0019] Each R 2 Each is independently selected from hydrogen and C1-C6 alkyl groups;
[0020] Each R 3 Each is independently selected from hydrogen, C1-C6 alkyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, and halogens;
[0021] Each R 4Each is independently selected from hydrogen, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, C3-C8 cycloalkyl group, and 3-8 heterocyclic group;
[0022] Each R 5 Each is independently selected from hydrogen, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group;
[0023] Each R 6 Each is independently hydrogen, C1-C6 alkyl group, C1-C6 alkyl group substituted with a halogen, C1-C6 alkyl group substituted with a C1-C6 alkoxy group, C1-C6 alkoxy group, C1-C6 alkoxy group substituted with a C1-C6 alkoxy group, C1-C6 alkylthio group, halogen, cyano group, -C(=O)R, nitro group, hydroxyl group, thiol group, amino group, R 5 An aryl group substituted or unsubstituted with R 5 Selected from a 5-10-membered heteroaryl group that is substituted or unsubstituted;
[0024] Each R is independently selected from hydrogen, hydroxyl group, hydroxyamino group, amino group, halogen, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylthio group, and C1-C6 alkylamine group.
[0025] In some embodiments, the indole fused saturated cyclic compound or its derivative has a structure represented by formula (III) or formula (IV):
[0026]
[0027] In some embodiments, the indole-fused saturated cyclic compound or its derivative has a structure represented by formula (V-1), formula (V-2), formula (V-3), formula (V-4), formula (V-5), formula (V-6), formula (V-7) or (V-8):
[0028]
[0029] In some embodiments, each R 2 is selected from hydrogen and C1-C3 alkyl groups.
[0030] In some embodiments, each R 2 It is selected from hydrogen, methyl group, and ethyl group.
[0031] In some embodiments, X 1 , X 2 are independently -O-, -S-, -C(R 1 )2-, -NR 2 Selected from;
[0032] Z 1 , Z 2 and Z 3 CR each independently 3 , is selected from N;
[0033] Each R 1 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, fluorine, chlorine, and bromine;
[0034] Each R 2 Each is independently selected from hydrogen and C1-C3 alkyl groups;
[0035] Each R 3 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, and halogens.
[0036] In some embodiments, X 1 is selected from -O-, -S-, and X 2 is -NR 2 - and, R 2 It is selected from hydrogen, methyl group, ethyl group, and propyl group.
[0037] In some embodiments, Z 1 , Z 2 and Z 3 0 or 1 of them are N, and the rest are all CR 3 is, R 3It is selected from hydrogen, methyl group, ethyl group, and propyl group.
[0038] In some embodiments, each R 4 Each is independently selected from hydrogen, C1-C3 alkyl group, C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, C3-C6 cycloalkyl group, and 3-6 heterocyclic group.
[0039] In some embodiments, each R 4 Each is independently selected from hydrogen, methyl group, ethyl group, propyl group, methoxy group, ethoxy group, propoxy group, methylthio group, ethylthio group, propylthio group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, oxetanyl group, tetrahydrofuranyl group, oxacyclohexyl group, tetrahydropyrrolyl group, and tetrahydrothienyl group.
[0040] In some embodiments, each R 5 Each is independently selected from hydrogen, C1-C3 alkyl group, C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group.
[0041] In some embodiments, each R 5 Each is independently selected from hydrogen, methyl group, ethyl group, propyl group, methoxy group, ethoxy group, propoxy group, methylthio group, ethylthio group, propylthio group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group.
[0042] In some embodiments, each R 6Each is independently hydrogen, C1-C3 alkyl group, C1-C3 alkyl group substituted with a halogen, C1-C3 alkyl group substituted with a C1-C3 alkoxy group, C1-C3 alkoxy group, C1-C3 alkoxy group substituted with a C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, -C(=O)R, nitro group, hydroxyl group, thiol group, amino group, R 5 A phenyl group substituted or unsubstituted with R 5 Naphthyl group substituted or unsubstituted with R 5 Selected from a 5-6 member heteroaryl group that is substituted or unsubstituted;
[0043] Each R is independently selected from hydrogen, hydroxyl group, hydroxyamino group, amino group, halogen, C1-C3 alkyl group, C1-C3 alkoxy group, and C1-C3 alkylamine group.
[0044] In some embodiments, each R 6 Each is independently hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, methoxy group, ethoxy group, propoxy group, methylthio group, ethylthio group, propylthio group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, -C(=O)NHOH, formyl group, acetyl group, methoxycarbonyl group, ethoxycarbonyl group, carbamoyl group, nitro group, hydroxyl group, thiol group, amino group, methyl group substituted with a methoxy group, ethyl group substituted with a methoxy group, propyl group substituted with a methoxy group, methoxy group substituted with a methoxy group, ethoxy group substituted with a methoxy group, propoxy group substituted with a methoxy group, phenyl group, naphthyl group, pyridyl group, pyrazinyl group, pyridazinyl group, pyrimidinyl group, It is selected from triazolyl groups, tetrazolyl groups, furanyl groups, thienyl groups, phylrolyl groups, and imidazolyl groups.
[0045] In some embodiments, Q is hydrogen, and one or more R 4 A C1-C3 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C3 alkoxy group substituted or unsubstituted with , one or more R 4It is selected from substituted or unsubstituted C1-C3 alkylthio groups, halogens, cyano groups, aldehyde groups, carboxyl groups, nitro groups, and hydroxyl groups.
[0046] In some embodiments, Q is selected from hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, monofluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group.
[0047] In some embodiments, Q is selected from chlorine, bromine, and cyano groups.
[0048] In some embodiments, L is hydrogen, and one or more Rs 4 A C1-C3 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C3 alkoxy group substituted or unsubstituted with , one or more R 4 A C1-C3 alkylthio group substituted or unsubstituted with, a halogen, a cyano group, an aldehyde group, a carboxyl group, a nitro group, a hydroxyl group, one or more R 5 A C3-C6 cycloalkyl group substituted or unsubstituted with, one or more R 5 A 3-6 binary heterocyclic ring substituted or unsubstituted with R, one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A naphthyl group substituted or unsubstituted with, one or more R 6 A 5-6 member heteroaryl group substituted or unsubstituted with, Selected from;
[0049] X 1 , X 2 are independently -O-, -S-, -C(R 1 )2-, -NR 2 Selected from;
[0050] Z 1 , Z 2 and Z 3 CR each independently 3, selected from N;
[0051] Each R 1 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, and halogens;
[0052] Each R 2 Each is independently selected from hydrogen and C1-C3 alkyl groups;
[0053] Each R 3 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, and halogens;
[0054] Each R 4 Each is independently selected from hydrogen, C1-C3 alkyl group, C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, C3-C6 cycloalkyl group, and 3-6 heterocyclic group;
[0055] Each R 5 Each is independently selected from hydrogen, C1-C3 alkyl group, C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group;
[0056] Each R 6 Each is independently hydrogen, C1-C3 alkyl group, C1-C3 alkyl group substituted with a C1-C3 alkoxy group, C1-C3 alkoxy group, C1-C3 alkoxy group substituted with a C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, C(=O)R, nitro group, hydroxyl group, thiol group, amino group, R 5 A phenyl group substituted or unsubstituted with R 5 Naphthyl group substituted or unsubstituted with R 5 Selected from a 5-6 member heteroaryl group that is substituted or unsubstituted;
[0057] Each R is independently selected from hydrogen, hydroxyl group, hydroxyamino group, amino group, halogen, C1-C3 alkyl group, C1-C3 alkoxy group, and C1-C3 alkylamine group.
[0058] In some embodiments, L is hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, monofluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, oxetanyl group, tetrahydrofuranyl group, oxacyclohexyl group, tetrahydropyrrolyl group, tetrahydrothienyl group, tetrahydropyrrolyl group substituted with a halogen, tetrahydropyrrolyl group substituted with a hydroxyl group, azetidinyl group, azetidinyl group substituted with a halogen, azetidinyl group substituted with a hydroxyl group, one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A naphthyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 A pyridazinel group substituted or unsubstituted with, one or more R 6 A pyrimidinyl group substituted or unsubstituted with, Selected from;
[0059] Each R 6Each is independently hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, methoxy group, ethoxy group, propoxy group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, -C(=O)NHOH, formyl group, acetyl group, methoxycarbonyl group, ethoxycarbonyl group, carbamoyl group, nitro group, hydroxyl group, thiol group, amino group, methyl group substituted with a methoxy group, ethyl group substituted with a methoxy group, propyl group substituted with a methoxy group, methoxy group substituted with a methoxy group, ethoxy group substituted with a methoxy group, propoxy group substituted with a methoxy group, phenyl group, naphthyl group, pyridyl group, pyrazinyl group, pyridazinyl group, pyrimidinyl group, triazolyl group, tetrazolyl group, furanyl group, It is selected from thienyl groups, phylrolyl groups, and imidazolyl groups.
[0060] In some embodiments, L is
[0061]
[0062]
[0063] Selected from.
[0064] In some embodiments, Q is selected from halogens and cyano groups;
[0065] L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Pyridazinyl group substituted or unsubstituted, Selected from; where, each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH.
[0066] In some embodiments, Q is selected from chlorine, bromine, and cyano groups;
[0067]
[0068] Selected from.
[0069] In some embodiments, the indole fused saturated cyclic compound or its derivative has a structure represented by formula (V-1),
[0070]
[0071] Here, Q is cyano-;
[0072] L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazinyl groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH;
[0073] Preferably, L is
[0074]
[0075] Selected from;
[0076] More preferably, L is Selected from.
[0077] In some embodiments, the indole fused saturated cyclic compound or its derivative has a structure represented by formula (V-3),
[0078]
[0079] Here, Q is cyano-;
[0080] L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazinyl groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH;
[0081] Preferably, L is
[0082]
[0083] Selected from;
[0084] More preferably, L is Selected from.
[0085] In some embodiments, the indole fused saturated cyclic compound or its derivative has a structure represented by formula (V-5),
[0086]
[0087] Here, Q is cyano-;
[0088] L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazinyl groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH;
[0089] Preferably, L is
[0090]
[0091] Selected from;
[0092] More preferably, L is Selected from.
[0093] In some embodiments, the indole fused saturated cyclic compound or its derivative has a structure represented by formula (V-1),
[0094]
[0095] In the above formula, Q is chlorine or bromine;
[0096] L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazinyl groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH;
[0097] Preferably, L is
[0098]
[0099] Selected from;
[0100] More preferably, L is Selected from. Effects of the invention
[0101] The present invention further provides applications of the above-described indole-fused saturated cyclic compounds or derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salts thereof, solvates thereof, or prodrug molecules thereof, and comprises the following technical solutions.
[0102] The indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuterium, or its tritium, according to the present invention, is applied in the manufacture of XOR inhibitors and / or URAT1 inhibitors.
[0103] The indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuterium, or its tritium, according to the present invention are applied in the manufacture of uric acid-lowering drugs.
[0104] The indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuterium, or its tritium, according to the present invention, is applied in the manufacture of drugs for the prevention and / or treatment of gout or hyperuricemia.
[0105] The present invention further provides an XOR / URAT1 dual inhibitor, the active ingredient of which contains an indole-fused saturated cyclic compound according to the present invention or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof.
[0106] The present invention further provides a uric acid-lowering drug characterized by being prepared with an active ingredient and a pharmaceutically acceptable auxiliary substance, wherein the active ingredient comprises an indole-fused saturated cyclic compound according to the present invention or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof.
[0107] The present invention further provides a method for preventing and / or treating gout or hyperuricemia, and
[0108] A step of administering a safe and effective amount of the indole-fused saturated cyclic compound according to the present invention or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuterium thereof, or a tritium thereof to a patient with gout or hyperuricemia; and / or
[0109] The method includes the step of administering a safe and effective amount of a uric acid-lowering drug according to the present invention to a patient with gout or hyperuricemia.
[0110] The indole-fused saturated cyclic compound or derivative thereof according to the present invention is a type of compound with a novel structure, and the compound has excellent inhibitory activity against both xanthine oxidase and uric acid transporters, and as a dual XOR / URAT1 inhibitor, has an excellent uric acid-lowering effect, excellent stability, good pharmacokinetic characteristics, and high potential for drug development, so it can be used in the manufacture of uric acid-lowering drugs for the prevention and / or treatment of gout or hyperuricemia. Brief explanation of the drawing
[0111] Figure 1 shows the blood uric acid concentrations in mice 8 hours after administration of compound 1 and compound 6. Specific details for implementing the invention
[0112] To aid in understanding the present invention, the invention is described more comprehensively below. The present invention may be implemented in various different forms and is not limited to the embodiments described herein. Conversely, the purpose of providing these embodiments is to enable a more complete understanding of the contents disclosed in the present invention.
[0113] In the following examples, experimental methods for which specific conditions are not specified generally follow general conditions or conditions recommended by the manufacturer. All common chemical reagents used in the examples are commercially available products.
[0114] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by a person skilled in the art to which this invention pertains. The terms used in the specification of this invention are for the purpose of describing specific embodiments only and are not intended to limit the invention. The term “and / or” used in this invention includes any combination of one or more of the related items and all combinations.
[0115] Additionally, as used in this invention, the term “or” is a comprehensive “or” designation and is equivalent to the term “and / or” unless the context explicitly indicates otherwise. The term “based on” is not exclusive and allows for being based on other unexplained factors unless the context explicitly indicates otherwise. Furthermore, throughout the specification, the meanings of “one,” “a kind,” and “above / corresponding” include multiple references. The meaning of “...among” includes “...among” and “...on”.
[0116] In the compound according to the present invention, any variable (e.g., R 4 , R 5Where (etc.) appear more than once in any constituent, the definition for each appearance is independent of the definition for other appearances. Likewise, combinations of substituents and variables are permitted insofar as such combinations make the compound stable. A line drawn from a substituent into the ring system indicates that the corresponding bond can be connected to any substitutable ring atom. If the ring system is polycyclic, this means that such bonds are connected only to any suitable carbon atom of an adjacent ring. A person skilled in the art should understand that the substituents and substitution forms of the compounds of the present invention can be selected to provide a compound that is chemically stable and can be easily synthesized from raw materials readily obtainable by the art of the art and the methods presented below. It should be understood that where a substituent itself is substituted by more than one group, these groups may be connected to the same carbon atom or different carbon atoms, provided that the structure is stable.
[0117] As used herein, the term “alkyl group” means comprising branched and straight-chain saturated aliphatic hydrocarbon groups having a specific number of carbon atoms. For example, in “C1-C6 alkyl group,” the definition of “C1-C6” includes groups arranged in a straight or branched chain and having 1, 2, 3, 4, 5, or 6 carbon atoms. For example, “C1-C6 alkyl group” specifically includes methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, pentyl, and hexyl groups.
[0118] As used herein, the term “cycloalkyl group” means a saturated or partially unsaturated monocyclic, bicyclic, or polycyclic cyclic hydrocarbon group in which the ring atoms are carbon atoms, and the bicyclic or polycyclic includes spiro rings, condensation rings, and crosslinking rings. For example, “cycloalkyl group” includes cyclopropyl groups, cyclobutyl groups, cyclopentyl groups, cyclohexyl groups,
[0119] It includes, but is not limited to, qi such as the back.
[0120] The term “alkoxy group” as used in this specification refers to a group having an -O-alkyl structure, such as -OCH3, -OCH2CH3, -OCH2CH2CH3, -O-CH2CH(CH3)2, -OCH2CH2CH2CH3, -O-CH(CH3)2, etc.
[0121] As used herein, the terms “heterocycloalkyl group” or “heterocyclic group” mean a saturated or partially unsaturated cyclic substituent of a single ring, double ring, or polycyclic group, wherein one or more ring atoms are heteroatoms selected from N, O, or S(O)m (where m is an integer from 0 to 2), and the remaining ring atoms are carbons, and the double ring or polycyclic group includes a spiro ring, a condensation ring, and a cross-linked ring. For example, oxetanyl group, azetidinyl group, morpholinyl group, piperidinyl group, tetrahydropyrrolyl group, pyrrolidinyl group, dihydroimidazolyl group, dihydroisothiazolyl group, dihydrooxadiazolyl group, dihydrooxazolyl group, dihydropyrazinyl group, dihydropyrazolyl group, dihydropyridinyl group, dihydropyrimidinyl group, dihydropyrrolyl group, dihydrotetrazolyl group, dihydrothiazolyl group, dihydrothiazolyl group, dihydrothiazolyl group, dihydroazetidinyl group, tetrahydrofuranyl group, tetrahydrothienyl group, Etc., and their N-oxides are included. The linkage of heterocyclic substituents can be implemented through carbon atoms or through heteroatoms.
[0122] As used herein, “heteroaryl group” means an aromatic ring containing one or more heteroatoms selected from O, N, or S, said aromatic ring may be a single ring, a double ring, or a polycyclic ring, and includes, but is not limited to, examples, quinolinyl group, pyrazolyl group, pyrrolyl group, thienyl group, furanyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, pyridazinyl group, triazolyl group, tetrazolyl group, imidazolyl group, oxazolyl group, isoxazolyl group, etc.; “heteroaryl group” is also understood to include an N-oxide derivative of any heteroaryl group containing nitrogen. The linkage of the heteroaryl group may be realized through carbon atoms or heteroatoms.
[0123] As understood by those skilled in the art, “halogen (“halo”) or “halo” as used herein means chlorine, fluorine, bromine, and iodine.
[0124] The present invention comprises the free form of a compound of Formula (I) or Formula (II), and also comprises pharmaceutically acceptable salts and stereoisomers thereof. The pharmaceutically acceptable salts included comprise not only exemplary salts of specific compounds according to this specification, but also typical pharmaceutically acceptable salts of the free form of all compounds of Formula (I) or Formula (II). The free form of a specific salt of said compound can be separated using techniques known in the art. The pharmaceutically acceptable salts of the present invention may be synthesized by conventional chemical methods from compounds of the present invention containing a basic portion or an acidic portion. Generally, salts of basic compounds may be prepared by using ion exchange chromatography, or by reacting a free base with an inorganic acid or organic acid in the required salt form in stoichiometric amounts or excess in a suitable solvent or a mixture of two or more solvents. Similarly, salts of acidic compounds are formed through a reaction with a suitable inorganic base or organic base.
[0125] Accordingly, pharmaceutically acceptable salts of the compounds of the present invention include conventional non-toxic salts of the compounds of the present invention formed by the reaction of the basic compounds of the present invention with inorganic acids or organic acids. For example, conventional non-toxic salts include salts obtained from inorganic acids such as hydrochloric acid, hydrobromide, sulfuric acid, aminosulfonic acid, phosphoric acid, nitric acid, etc., and also include salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, parmoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, hydroxyethylsulfonic acid, trifluoroacetic acid, etc.
[0126] If the compound of the present invention is acidic, a suitable “pharmaceuticalally acceptable salt” means a salt prepared from a pharmaceutically acceptable non-toxic base comprising an inorganic base and an organic base. Salts obtained from inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, manganese monophosphate salts, potassium salts, sodium salts, and zinc salts. Ammonium salts, calcium salts, magnesium salts, potassium salts, and sodium salts are particularly preferred. In the case of salts obtained from a pharmaceutically acceptable organic non-toxic base, said base comprises primary amines, secondary amines and tertiary amines, substituted amines (including naturally occurring substituted amines and cyclic amines), and basic ion exchange resins, etc. The above bases include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucoseamine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, aminobutantriol, etc.
[0127] Berg et al., “Pharmaceutical Salts,” J. Pharm. Sci.’1977:66:1–19, describe in more detail the preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts.
[0128] Metabolites of the compounds mentioned in the present invention and pharmaceutically acceptable salts thereof, and prodrugs that can be converted in the body into the structure of the compounds mentioned in the present invention and pharmaceutically acceptable salts thereof are also included in the claims of the present invention.
[0129] A uric acid-lowering drug according to the present invention, and a drug or method for the prevention and / or treatment of gout or hyperuricemia, comprises the step of administering to a patient or subject an active ingredient within a safe-effective dose range (i.e., an indole-fused saturated cyclic compound according to the present invention or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof) and a pharmaceutically acceptable auxiliary substance. When administering the drug, a safe-effective dose of the active ingredient is administered to a mammal (e.g., a human) requiring treatment, wherein the dose administered is a dose recognized as pharmaceutically effective. Of course, specific doses must also take into account factors such as the route of administration and the patient's health condition, and these fall within the scope of the expertise of a skilled physician.
[0130] The “active ingredient” according to the present invention refers to a compound of formula (I) or formula (II) according to the present invention or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof.
[0131] “Safe and effective dose” refers to an amount of active ingredient sufficient to significantly improve symptoms without causing serious side effects. Typically, the pharmaceutical composition contains 1 to 2,000 mg of active ingredient, more preferably 10 to 200 mg, per unit dose. Preferably, the “unit dose” is one tablet.
[0132] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., human) requiring treatment, wherein the dosage at the time of administration is a dosage recognized as pharmaceutically effective. Based on a person weighing 60 kg, the daily dosage is generally 1 to 2000 mg, and preferably 20 to 500 mg. Of course, the specific dosage must also take into account factors such as the route of administration and the patient's health condition, and these fall within the scope of expertise of a skilled physician.
[0133] “Pharmaceuticalally acceptable auxiliary substances” means one or more compatible solid or liquid fillers or gel substances suitable for use in humans, and must have sufficient purity and sufficiently low toxicity.
[0134] “Compatibility” means that each component in the composition can be mixed with the active ingredient of the present invention and can also be mixed with each other, without significantly reducing the efficacy of the active ingredient.
[0135] Some examples of pharmaceutically acceptable carriers or auxiliary materials include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., Tween®), wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, non-pyrolytic raw water, etc.
[0136] In another preferred example, the compound of Formula (I) or Formula (II) of the present invention may form a complex with a macromolecular compound or polymer through a non-bonding action. In another preferred example, the compound of Formula (I) or Formula (II) of the present invention may be connected to a macromolecular compound or polymer compound through chemical bonding. The macromolecular compound may be a biomacromolecule such as a polysaccharide, protein, nucleic acid, polypeptide, etc.
[0137] There are no specific limitations on the method of administration of the active ingredient or pharmaceutical composition of the present invention, and representative methods of administration include, but are not limited to, oral administration, intratumoral administration, rectal administration, and parenteral administration (intravenous, intramuscular, or subcutaneous).
[0138] Solid formulations for oral administration include capsules, tablets, pills, powders, and granules.
[0139] In these solid formulations, the active ingredient is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or calcium phosphate, or mixed with the following ingredients.
[0140] (a) Fillers or extenders, e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid;
[0141] (b) binders, e.g., hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic;
[0142] (c) Humectants, e.g., glycerin;
[0143] (d) disintegrants, e.g., agar, calcium carbonate, potato starch or tapioca starch, agilic acid, certain complex silicates and sodium carbonate;
[0144] (e) Dissolution retardant, e.g., paraffin;
[0145] (f) absorption promoter, e.g., quaternary ammonium compound;
[0146] (g) Humectants, e.g., cetyl alcohol and glyceryl monostearate;
[0147] (h) Adsorbent, e.g., kaolin; and
[0148] (i) Lubricants, e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the formulation may include a buffer.
[0149] The solid formulations described above may be prepared using coating and shell materials, such as enteric coatings and other materials known in the art. These may include opacifying agents, and the release of the active ingredient in these compositions may be delayed and released in specific parts of the digestive tract. Examples of usable embedding ingredients include polymeric materials and paraffinic materials.
[0150] Liquid formulations for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active ingredient, the liquid formulation may include inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil, and sesame oil, or mixtures of these substances. In addition to these inert diluents, the composition may include adjuvants such as humectants, emulsifiers and suspending agents, sweeteners, stimulants, and flavorings.
[0151] In addition to the active ingredient, the suspension may include a suspending agent, such as ethoxylated isooctadecanol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or a mixture of these materials.
[0152] A parenteral injectable composition may comprise a physiologically acceptable sterile aqueous or non-aqueous solution, dispersion, suspension, or emulsion, and a sterile powder for redissolving into a sterile injectable solution or dispersion. Suitable aqueous and non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.
[0153] The compounds of the present invention may be administered alone or in combination with other drugs known to treat or improve similar conditions. When administered in combination, the method and dosage of administration of the existing drugs remain unchanged, and the compounds of Formula (I) or Formula (II) are administered simultaneously or sequentially. When the compounds of Formula (I) or Formula (II) are taken simultaneously with one or more other drugs, a pharmaceutical composition containing the compounds of Formula (I) or Formula (II) and one or more known drugs simultaneously is preferably used. Drug combination also includes taking the compounds of Formula (I) or Formula (II) and one or more known drugs at overlapping times. When the compounds of Formula (I) or Formula (II) are taken in combination with one or more other drugs, the dosage of the compounds of Formula (I) or Formula (II) or the known drugs may be lower than the dosage when they are administered alone.
[0154] The present invention is described in more detail below with specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the invention. In the following examples, experimental methods for which specific conditions are not specified generally follow general conditions or conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated based on weight.
[0155] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as understood by a person skilled in the art. Additionally, any methods and materials similar to or equivalent to those described may be applied to the method of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.
[0156] The raw materials in the following examples may be obtained through commercial channels, manufactured by methods already known in the art, or manufactured according to the methods described herein.
[0157] The description of the abbreviations of the raw material reagents used in the following examples is as follows.
[0158] NIS: N-iodosuccinimide;
[0159] TEA: Triethylamine;
[0160] DMF: N,N-dimethylformamide;
[0161] THF: Tetrahydrofuran;
[0162] TFA: Trifluoroacetic acid;
[0163] DIPEA: N,N-diisopropylethylamine;
[0164] HATU: 2-(7-Azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate;
[0165] DMSO: Dimethyl sulfoxide;
[0166] NMP: N-methylpyrrolidone;
[0167] NBS: N-bromosuccinimide;
[0168] NCS: N-chlorosuccinimide;
[0169] NaHMDS: Bis(trimethylsilyl)aminosodium;
[0170] DMAc: N,N-dimethylacetamide;
[0171] LAH: Lithium aluminum hydride.
[0172] Example 1 Preparation of Compound 1
[0173]
[0174] Step 1: Synthesis of 4-iodo-5-amino-1,3-dihydroisobenzofuran (Intermediate 1-1)
[0175] 5-amino-1,3-dihydroisobenzofuran (10 g, 0.074 mol) and NIS (16.6 g, 0.074 mol) were added to acetonitrile (200 ml). The mixture was stirred at 25°C for 4 hours, concentrated, water was added to continue the reaction, and the mixture was extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a pale yellow solid product (4.4 g, 23%).
[0176] 1 H NMR (400 MHz, CDCl3) δ 6.95 (d, J =8.0 Hz, 1H), 6.64 (d, J =8.0 Hz, 1H), 5.19 (s, 2H), 4.96 (s, 2H).
[0177] Step 2: Synthesis of 4-trimethylsilylethynyl-5-amino-1,3-dihydroisobenzofuran (Intermediates 1-2)
[0178] 4-iodo-5-amino-1,3-dihydroisobenzofuran (2.0 g, 7.66 mmol), trimethylsilylacetylene (2.7 ml, 19.16 mmol), CuI (1.46 g, 7.66 mmol), and Pd(dppf)Cl2 (1.1 g, 1.53 mmol) were added to triethylamine (25 ml). The mixture was then reacted at 80°C for 12 hours. After concentration, water was added to continue the reaction, and the mixture was extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow solid product (0.9 g, 51.5%).
[0179] 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J= 8.4 Hz, 1H), 6.61 (d, J= 8.4 Hz, 1H), 5.08 (s, 2H), 5.03 (s, 2H), 0.26 (s, 9H).
[0180] Step 3: Synthesis of 3,6-Dihydro-1H-furo[3,4-e]indole (Intermediate 1-3)
[0181] 4-trimethylsilylethynyl-5-amino-1,3-dihydroisobenzofuran in DFM (70 ml) ( 4.4g (19.02 mmol) and CuI (7.24g, 38 mmol) were added. Subsequently, the reaction was carried out at 120°C for 2 hours. After concentration, water was added to process the reaction, and the product was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a yellow solid product (1.79g, 59%).
[0182] MS (ESI) calcd for C 10 H9NO: 159.07; found: 160.00 [M+1].
[0183] 1 H NMR (400 MHz, CDCl3) δ 8.32 (brs, 1H), 7.34 (d, J =8.0 Hz,1H), 7.27 (s, 1H), 7.07 (d, J =8.0 Hz, 1H), 6.42 (s, 1H), 5.37-5.36 (m, 2H), 5.25-5.24 (m, 2H).
[0184] Step 4: Synthesis of 8-formyl-3,6-dihydro-1H-furo[3,4-e]indole (intermediates 1-4)
[0185] 3,6-dihydro-1H-furo[3,4-f]indole (600 mg, 3.77 mmol) and POCl3 (694 mg, 4.53 mmol) were added to DFM (100 ml). The mixture was then reacted at room temperature for 3 hours. Subsequently, an aqueous NaOH solution (2.0 M) was added, and the mixture was heated to 70°C and reacted for 0.5 hours. The mixture was extracted with ethyl acetate, the organic phase was dried, and the solvent was removed by concentrating under reduced pressure to obtain a red solid product (449 mg, 64%).
[0186] MS (ESI) calcd for C 11 H9NO2: 187.06; found: 188.15 [M+1].
[0187] 1 H NMR (400 MHz, DMSO-D6) δ 12.26 (brs, 1H), 9.78 (s, 1H), 8.28 (s, 1H), 7.41 (d, J =8.0 Hz, 1H), 7.18 (d, J =8.4 Hz, 1H), 5.39-5.38 (m, 2H), 5.09-5.07 (m, 2H).
[0188] Step 5: Synthesis of 8-cyano-3,6-dihydro-1H-furo[3,4-e]indole (intermediates 1-5)
[0189] 8-formyl-3,6-dihydro-1H-furo[3,4-e]indole (449 mg, 2.43 mmol), hydroxylamine hydrochloride (337 mg, 4.85 mmol), and pyridine (770 mg) were added to THF (5 ml). After reacting at 80°C for 12 hours, acetic anhydride (2.3 ml) was added and reacted for 12 hours. Subsequently, an aqueous NaOH solution (2.0 M) was added at room temperature, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow solid product (450 mg, 100%).
[0190] MS (ESI) calcd for C 11 H8N2O: 184.06; found: 183.00 [M-1].
[0191] Step 6: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid tert-butyl ester (intermediate 1-6)
[0192] 8-cyano-3,6-dihydro-1H-furo[3,4-e]indole (50 mg, 0.27 mmol), Cs2CO3 (132 mg, 0.4 mmol), and 4-fluorobenzoic acid tert-butyl ester (80 mg, 0.4 mmol) were added to DMF (1 ml). The mixture was reacted at 80°C for 12 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a pale white solid product (30 mg, 31%).
[0193] MS (ESI) calcd for C 22 H 20 N2O2: 360.15 ; found: 361.15 [M+1].
[0194] 1 H NMR (400 MHz, CDCl3) δ 8.20 (d, J =8.4 Hz, 2H), 7.84 (s, 1H), 7.55 (d, J =8.4 Hz, 2H), 7.45 (d, J =8.4 Hz, 1H), 7.23 (d, J =8.4 Hz, 1H), 5.57 (s, 1H), 5.23-5.24 (m, 1H), 1.64 (s, 9H)
[0195] Step 7: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid (Compound 1)
[0196] 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid tert-butyl ester (30 mg, 0.08 mmol) was added to TFA (1 ml). After reacting at 60°C for 3 hours, water was added to process the reaction, and the mixture was filtered to obtain a pale white solid product, which was then dried to obtain the target product (24 mg, 95%).
[0197] MS (ESI) calcd for C 18 H 12N2O3: 304.08; found: 303.05 [M-1].
[0198] 1 H NMR (400 MHz, DMSO-D6) δ 13.28 (s, 1H), 8.71 (s, 1H), 8.17 (d, J =8.4 Hz, 2H), 7.80 (d, J =8.4 Hz, 2H), 7.61 (d, J =8.4 Hz, 1H), 7.35 (d, J =8.4 Hz, 1H), 5.40 (s, 2H), 5.14 (s, 2H).
[0199] Example 2 Preparation of Compound 6
[0200]
[0201] Step 1: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)benzoate ethyl ester (intermediate 6-1)
[0202] 8-cyano-3,6-dihydro-1H-furo[3,4-e]indole (520 mg, 2.83 mmol), Cs2CO3 (1.4 g, 4.34 mmol), and 4-fluoro-2-(methoxymethyleneoxy)benzoate ethyl ester (968 mg, 4.34 mmol) were added to DMF (10 ml). The mixture was reacted at 85°C for 12 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a pale white solid product (258 mg, 23%).
[0203] MS (ESI) calcd for C 22 H20N2O5: 392.14; found: 393.05 [M+1].
[0204] Step 2: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-ethyl hydroxybenzoate (intermediate 6-2)
[0205] 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)benzoate ethyl ester (1.4g, 3.57mmol), EtOH (10ml), and HCl (2.0M, 14ml) were added to THF (20ml). After reacting at 70°C for 12 hours, the mixture was cooled to room temperature. After filtration, the mixture was washed with EtOH and H2O and dried to obtain a pale white solid product (1.1g, 88%).
[0206] MS (ESI) calcd for C 20 H 16 N2O4: 348.11; found: 349.10 [M+1].
[0207] Step 3: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-hydroxybenzoic acid (Compound 6)
[0208] 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-ethyl hydroxybenzoate (60 mg, 0.17 mmol), H2O (0.6 ml), and LiOH (43 mg) were added to THF (2 ml). After reacting at room temperature for 24 hours, HCl (2.0 M) was added to acidify the mixture. A pale white solid product was obtained by filtration, washed with H2O and EtOH, and dried to obtain the target product (50 mg, 91%).
[0209] MS (ESI) calcd for C 18 H 12 N2O4: 320.08; found: 319.00 [M-1].
[0210] 1 H NMR (400 MHz, DMSO-D6) δ 8.68 (s, 1H), 8.00 (d, J=8.4 Hz, 1H), 7.63 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.27-7.22 (m, 2H), 5.40 (s, 2H), 5.14 (s, 2H).
[0211] Example 3 Preparation of Compound 12
[0212]
[0213] Step 1: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)benzoic acid (intermediate 12-1)
[0214] 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)benzoate ethyl ester (200 mg, 0.51 mmol), H2O (1.0 ml), and LiOH (107 mg) were added to a mixed solvent of THF (3 ml) and ethanol (3 ml). After reacting at room temperature for 12 hours, HCl (2.0 M) was added to acidify the mixture. A pale white solid product was obtained by filtration, washed with H2O and EtOH, and dried to obtain the target product (159 mg, 85%).
[0215] MS (ESI) calcd for C 20 H 16 N2O5: 364.11 ; found: 363.00 [M-1].
[0216] Step 2: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)-N-(OTHP)benzamide (Compound 12-2)
[0217] 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)benzoic acid (157 mg, 0.43 mmol), DIPEA (166 mg), HATU (327 mg, 0.86 mmol), and NH2OTHP (114 mg, 0.65 mmol) were added to DMF (3 ml). After reacting at room temperature for 12 hours, water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow solid product (120 mg, 60%).
[0218] MS (ESI) calcd for C 25 H 25 N3O6: 463.17 ; found: 464.05 [M+1].
[0219] 1H NMR (400 MHz, DMSO-d6) δ 11.31 (s, 1H), 8.68 (s, 1H), 7.70 (d, J =8.0 Hz, 1H), 7.59 (d, J =8.8 Hz, 1H), 7.47 (d, J =2.0 Hz, 1H), 7.39 (dd, J=8.0 and 2.0 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 5.41 (s, 2H), 5.39 (s, 2H), 5.14 (s, 2H), 5.06 (s, 1H), 4.05-4.00 (m, 1H), 3.56-3.53 (m, 1H), 3.44 (s, 3H), 1.75-1.73 (m, 3H), 1.57-1.55 (m, 3H).
[0220] Step 3: Synthesis of 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-N,2-dihydroxybenzamide (Compound 12)
[0221] 4-(8-cyano-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)-2-(methoxymethyleneoxy)-N-(OTHP)benzamide (30 mg, 0.26 mmol) and HCl (2.0 M, 0.3 ml) were added to a mixed solvent of THF (1 ml) and EtOH (0.5 ml). After reacting at 70°C for 12 hours, the mixture was cooled to room temperature. After filtration, the obtained solid was washed with EtOH and H2O and dried to obtain a pale red solid product (20 mg, 83%).
[0222] MS (ESI) calcd for C 18 H 13 N3O4:335.09 ; found: 336.00 [M+1].
[0223] 1 H NMR (400 MHz, DMSO-d6) δ 12.71 (brs, 1H), 11.62 (brs, 1H), 9.53 (s, 1H), 8.70 (s, 1H), 7.96 (d, J =8.8 Hz, 1H), 7.66 (d, J =8.4 Hz, 1H), 7.40 (d, J =8.4 Hz, 1H), 7.23-7.24 (m, 2H), 5.44 (s, 2H), 5.18 (s, 2H).
[0224] Example 4 Preparation of Compound 5
[0225]
[0226] Step 1: Synthesis of 4-(8-formyl-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzonitrile (intermediate 5-1)
[0227] 8-formyl-3,6-dihydro-1H-furo[3,4-e]indole (300 mg, 1.6 mmol), Cs2CO3 (1.0 g, 3.2 mmol), and 4-fluorobenzonitrile (310 mg, 2.6 mmol) were added to DMSO (5.0 ml). The reaction was carried out at 80°C for 12 hours, after which it was cooled to room temperature. Water was added to process the reaction, and the filter cake obtained by filtration was washed with water and ethanol and dried to obtain a pale white solid product (390 mg, 84%).
[0228] MS (ESI) calcd for C 18 H 12 N2O2: 288.09; found: 289.30 [M+1].
[0229] 1 H NMR (400 MHz, DMSO-D6) δ 9.91 (s, 1H), 8.73 (s, 1H), 8.15 (d, J=8.8 Hz, 2H), 7.94 (d, J=8.8 Hz, 2H), 7.54 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 5.45 (s, 2H), 5.13 (s, 2H).
[0230] Step 2: Synthesis of 8-formyl-6-(4-(1H-tetrazole-5-yl)phenyl)-3,6-dihydro-1H-furo[3,4-e]indole (intermediate 5-2)
[0231] 4-(8-formyl-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzonitrile (390 mg, 1.35 mmol), NaN3 (308 mg, 4.74 mmol), and triethylamine hydrochloride (372 mg) were added to NMP (6.0 ml). The reaction was carried out in a sealed tube at 120°C for 12 hours, after which it was cooled to room temperature. Hydrochloric acid (2.0 M) was added to adjust the pH of the reaction mixture to 3, and the mixture was stirred for half an hour. The filter cake obtained by filtration was washed with methanol and dried to obtain a brown solid product (420 mg, 95%).
[0232] MS (ESI) calcd for C 18 H 13 N5O2: 331.11; found: 332.25 [M+1].
[0233] 1 H NMR (400 MHz, DMSO-D6) δ 9.91 (s, 1H), 8.71 (s, 1H), 8.29 (d, J=8.4 Hz, 2H), 7.95 (d, J=8.4 Hz, 2H), 7.55 (d, J=8.8 Hz, 1H), 7.31 (d, J=8.8 Hz, 1H), 5.45 (s, 2H), 5.13 (s, 2H)
[0234] Step 3: Synthesis of 8-cyano-6-(4-(1H-tetrazole-5-yl)phenyl)-3,6-dihydro-1H-furo[3,4-e]indole (Compound 5)
[0235] 8-formyl-6-(4-(1H-tetrazole-5-yl)phenyl)-3,6-dihydro-1H-furo[3,4-e]indole (320 mg, 0.97 mmol), hydroxylamine hydrochloride (100 mg, 1.45 mmol), and sodium formate (197 mg) were added to formic acid (5.0 ml). After reacting at 105°F for 4 hours, water was added to process the reaction, and the filter cake obtained by filtration was thoroughly washed with methanol. The methanol solution was collected, concentrated under reduced pressure, and the solvent was removed to obtain the target product (50 mg, 15%).
[0236] MS (ESI) calcd for C 18 H 12 N6O: 328.11; found: 327.35 [M-1].
[0237] 1 H NMR (400 MHz, DMSO-D6) δ 8.72 (s, 1H), 8.27 (d, J=8.4 Hz, 2H), 7.92 (d, J=8.8 Hz, 2H), 7.63 (d, J=8.4 Hz, 1H), 7.36 (d, J=8.4 Hz, 1H), 5.40 (s, 2H), 5.14 (s, 2H).
[0238] Example 5 Preparation of Compound 49
[0239]
[0240] Step 1: Synthesis of 5-amino-4,6-dibromo-2,3-dihydroindene (intermediate 49-1)
[0241] 5-amino-2,3-dihydroindene (10.0 g, 75 mmol) and NBS (33.4 g, 188 mmol) were added to acetonitrile (400 ml). The mixture was stirred at room temperature for 4 hours, concentrated, water was added to continue the reaction, and the mixture was extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow liquid product (8.7 g, 40%).
[0242] Step 2: Synthesis of 5-amino-4-bromo-2,3-dihydro-1H-indene (Intermediate 49-2)
[0243] 5-amino-4,6-dibromo-2,3-dihydroindene (4.0 g, 14 mmol) and tin(II) chloride dihydrate (3.8 g, 17 mmol) were added to a mixed solvent of concentrated hydrochloric acid (15 ml) and HOAc (18 ml). After reacting for half an hour with stirring at 120°C, an aqueous NaOH solution (2.0 M) was added at room temperature to adjust the pH of the reaction mixture to 9, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a yellow liquid product (2.5 g, 84%).
[0244] 1 H NMR (400 MHz, CDCl3) δ 6.94 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 4.34 (br, 2H), 2.92 (t, J = 8.0 Hz, 2H), 2.90 (t, J = 8.0 Hz, 2H), 2.11-2.03 (m, 2H).
[0245] Step 3: Synthesis of 4-trimethylsilylethynyl-5-amino-2,3-dihydro-1H-indene (Intermediate 49-3)
[0246] 5-amino-4-bromo-2,3-dihydro-1H-indene (100 mg, 0.47 mmol), trimethylsilylacetylene (70 mg, 0.71 mmol), CuI (9.0 mg, 0.05 mmol), and Pd(dppf)Cl2 (34 mg, 0.05 mmol) were added to triethylamine (6 ml). Subsequently, the reaction was carried out at 80°C for 12 hours. After concentration, water was added to continue the reaction, and the mixture was extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a pale yellow liquid product (28 mg, 26%).
[0247] MS (ESI) calcd for C 14 H 19 NSi: 229.13; found: 230.35 [M+1].
[0248] Step 4: Synthesis of 3,6,7,8-tetrahydrocyclopenta[e]indole (intermediate 49-4)
[0249] 4-trimethylsilylethynyl-5-amino-2,3-dihydro-1H-indene (28 mg, 0.12 mmol) and CuI (47 mg, 0.24 mmol) were added to DMF (1 ml). After reacting at 120°C for 2 hours, the mixture was cooled to room temperature and filtered. The filtrate was concentrated to remove the solvent, and then purified by column chromatography to obtain a white solid product (10 mg, 53%).
[0250] MS (ESI) calcd for C 11 H 11 N: 157.09; found: 158.30 [M+1].
[0251] 1 H NMR (400 MHz, CDCl3) δ 8.14 (br, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.21-7.20 (m, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.47-6.45 (m, 1H), 3.11 (t, J = 7.6 Hz, 2H), 3.02 (t, J = 7.2 Hz, 2H), 2.23-2.16 (m, 2H).
[0252] Step 5: Synthesis of 1-formyl-3,6,7,8-tetrahydrocyclopenta[e]indole (intermediate 49-5)
[0253] 3,6,7,8-tetrahydrocyclopenta[e]indole (200 mg, 1.28 mmol) and POCl3 (197 mg, 1.28 mmol) were added to DMF (4.0 ml). Subsequently, the reaction was carried out at room temperature for 12 hours. An aqueous NaOH solution was added to adjust the pH of the reaction mixture to 9 to 12, and the mixture was heated to 70°C and reacted for 1 hour. Extraction was performed with dichloromethane, the organic phase was dried, and the solvent was removed by vacuum concentration. The product was then purified by column chromatography to obtain a yellow solid product (176 mg, 75%).
[0254] MS (ESI) calcd for C 12 H 11 NO: 185.08; found: 186.35 [M+1].
[0255] 1 H NMR (400 MHz, DMSO-d6) δ 12.11 (brs, 1H), 9.84 (s, 1H), 8.19 (d, J = 1.6 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 3.33 (t, J = 7.6 Hz, 2H), 2.92 (t, J = 7.6 Hz, 2H), 2.10-2.03 (m, 2H).
[0256] Step 6: Synthesis of 1-cyano-3,6,7,8-tetrahydrocyclopenta[e]indole (intermediate 49-6)
[0257] 1-formyl-3,6,7,8-tetrahydrocyclopenta[e]indole (176 mg, 0.96 mmol), hydroxylamine hydrochloride (133 mg, 1.91 mmol), and pyridine (300 mg) were added to THF (5.0 ml). The mixture was then reacted at 80°C for 12 hours. Acetic anhydride (985 mg) was added and the mixture was reacted for 7 hours. Subsequently, an aqueous NaOH solution (2.0 M) was added at room temperature to adjust the pH of the solution to 10 to 12, stirred for half an hour, and extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a pale white solid product (82 mg, 47%).
[0258] Step 7: Synthesis of 4-(1-cyano-7,8-dihydrocyclopenta[e]indole-3(6H)-yl)benzoic acid tert-butyl ester (intermediate 49-7)
[0259] 1-cyano-3,6,7,8-tetrahydrocyclopenta[e]indole (82 mg, 0.45 mmol), Cs2CO3 (295 mg, 0.91 mmol), and 4-fluorobenzoic acid tert-butyl ester (134 mg, 0.68 mmol) were added to DMF (3.0 ml). The mixture was reacted at 100°C for 12 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a colorless oily product (77 mg, 48%).
[0260] MS (ESI) calcd for C 23 H 22 N2O2: 358.17; found: 359.30 [M+1].
[0261] 1 H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 8.12 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 3.25 (t, J = 7.6 Hz, 2H), 2.98 (t, J = 7.6 Hz, 2H), 2.23-2.15 (m, 2H), 1.58 (s, 9H).
[0262] Step 8: Synthesis of 4-(1-cyano-7,8-dihydrocyclopenta[e]indole-3(6H)-yl)benzoic acid (Compound 49)
[0263] 4-(1-cyano-7,8-dihydroxycyclopenta[e]indole-3(6H)-yl)benzoic acid tert-butyl ester (77 mg, 0.22 mmol) was added to TFA (1 ml). After reacting at room temperature for 2 hours, the solvent was removed by concentration under reduced pressure, followed by washing with ethyl acetate and drying to obtain a white solid target product (37 mg, 56%).
[0264] MS (ESI) calcd for C 19 H14 N2O2: 302.11; found: 303.25 [M+1].
[0265] 1 H NMR (400 MHz, DMSO-d6) δ 13.26 (s, 1H), 8.63 (s, 1H), 8.16 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 1H), 7.28 (d, J = 8.4 Hz, 1H), 3.25 (t, J = 7.6 Hz, 2H), 2.98 (t, J = 7.6 Hz, 2H), 2.23-2.16 (m, 2H).
[0266] Example 6 Preparation of Compound 97
[0267]
[0268] Step 1: Synthesis of 8-chloro-3,6-dihydro-1H-furo[3,4-e]indole (intermediate 97-1)
[0269] 3,6-dihydro-1H-furo[3,4-e]indole (150 mg, 0.94 mmol) and NCS (126 mg, 0.94 mmol) were added to acetonitrile (6.0 ml). After reacting at room temperature for 4 hours, water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow solid product (158 mg, 85%).
[0270] MS (ESI) calcd for C 10 H8ClNO: 193.03; found: 192.40 [M-1].
[0271] 1 H NMR (400 MHz, CDCl3) δ 11.47 (s, 1H), 7.52 (d, J =2.8 Hz, 1H), 7.34 (d, J =8.4 Hz, 1H), 7.09 (d, J =8.0 Hz, 1H), 5.38 (s, 2H), 5.06 (s, 2H).
[0272] Step 2: Synthesis of 4-(8-chloro-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid tert-butyl ester (intermediate 97-2)
[0273] 8-chloro-3,6-dihydro-1H-furo[3,4-e]indole (155 mg, 0.8 mmol), Cs2CO3 (419 mg, 1.28 mmol), and 4-fluorobenzoic acid tert-butyl ester (252 mg, 0.128 mmol) were added to DMF (5.0 ml). The reaction was carried out at 80°C for 12 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a white solid product (210 mg, 71%).
[0274] 1 H NMR (400 MHz, CDCl3) δ 8.08 (d, J =8.4 Hz, 2H), 8.02 (s, 1H), 7.74 (d, J =8.4 Hz, 2H), 7.60 (d, J =8.4 Hz, 1H), 7.25 (d, J =8.4 Hz, 1H), 5.44 (s, 2H), 5.10 (s, 2H), 1.58 (s, 9H).
[0275] Step 3: Synthesis of 4-(8-chloro-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid (Compound 97)
[0276] 4-(8-chloro-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid tert-butyl ester (210 mg, 0.57 mmol) was added to TFA (2.0 mL). The mixture was reacted at room temperature for 1 hour, concentrated under reduced pressure to remove the solvent, slurried with methanol, filtered, and dried to obtain a white solid target product (150 mg, 84%).
[0277] MS (ESI) calcd for C 17 H 12ClNO3: 313.05; found: 312.30 [M-1].
[0278] 1 H NMR (400 MHz, CDCl3) δ 13.16 (s, 1H), 8.12 (d, J =8.4 Hz, 2H), 8.04 (s, 1H), 7.75 (d, J =8.8 Hz, 2H), 7.62 (d, J =8.8 Hz, 1H), 7.25 (d, J =8.4 Hz, 1H), 5.45 (s, 2H), 5.11 (s, 2H).
[0279] Example 7 Preparation of Compound 193
[0280]
[0281] Step 1: Synthesis of 8-bromo-3,6-dihydro-1H-puro[3,4-e]indole (intermediate 193-1)
[0282] 3,6-dihydro-1H-furo[3,4-e]indole (500 mg, 3.14 mmol) and NBS (448 mg, 2.5 mmol) were added to acetonitrile (10.0 ml). After reacting at room temperature for 3 hours, water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a brown solid product (70 mg, 10%).
[0283] MS (ESI) calcd for C 10 H8BrNO: 236.98, 238.98; found: 236.30, 238.30 [M-1].
[0284] Step 2: Synthesis of 4-(8-bromo-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid tert-butyl ester (intermediate 193-2)
[0285] 8-bromo-3,6-dihydro-1H-furo[3,4-e]indole (70 mg, 0.3 mmol), Cs2CO3 (192 mg, 0.6 mmol), and 4-fluorobenzoic acid tert-butyl ester (86 mg, 0.45 mmol) were added to DMF (1.5 ml). The mixture was reacted at 80°C for 12 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a white solid product (10 mg, 8%).
[0286] Step 3: Synthesis of 4-(8-bromo-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid (Compound 193)
[0287] 4-(8-bromo-1,3-dihydro-6H-furo[3,4-e]indole-6-yl)benzoic acid tert-butyl ester (5 mg, 0.02 mmol) was added to TFA (0.5 ml). After reacting at room temperature for 0.5 hours, the solvent was removed by concentration under reduced pressure, followed by washing with ethyl acetate and drying to obtain a brown solid target product (4 mg, 92%).
[0288] MS (ESI) calcd for C 17 H 11 BrNO3: 357.00, 359.00; found: 356.20, 358.20 [M-1].
[0289] 1 H NMR (400 MHz, DMSO-D6) δ 8.11 (s, 1H), 8.01 (d, J =8.4 Hz, 2H), 7.70 (d, J =8.4 Hz, 2H), 7.60 (d, J =8.4 Hz, 1H), 7.25 (d, J =8.4 Hz, 1H), 5.48 (s, 2H), 5.09 (s, 2H).
[0290] Example 8 Preparation of Compound 25
[0291]
[0292] Step 1: Synthesis of 5-amino-4,6-dibromo-2,3-dihydrobenzofuran (intermediate 25-1)
[0293] 5-amino-2,3-dihydrobenzofuran (5.0 g, 37.03 mmol) and bromine (17.8 g, 111.1 mmol) were added to acetic acid (100 ml) and reacted at room temperature for 12 hours with stirring. Saturated Na2SO3 solution was added and treated until the reaction solution turned yellow, sodium hydroxide aqueous solution (4.0 M) was added to adjust the pH of the reaction solution to 10, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a pale white solid product (4.3 g, 40%).
[0294] 1 HNMR (400MHz, DMSO- d 6 ) δ 6.92 (s, 1H), 4.76 (s, 2H), 4.50 (t, J = 8.8 Hz, 2H), 3.10 (t, J = 8.8 Hz, 2H).
[0295] Step 2: Synthesis of 5-amino-4-bromo-2,3-dihydrobenzofuran (intermediate 25-2)
[0296] 5-amino-4,6-dibromo-2,3-dihydrobenzofuran (11.8g, 40.41mmol) and tin(II) chloride dihydrate (10.0g, 44.45mmol) were added to a mixed solvent of concentrated hydrochloric acid (20ml) and HOAc (60ml), and the mixture was stirred at 120°C for 2 hours. Afterward, an aqueous NaOH solution (2.0M) was added at room temperature to adjust the pH of the reaction mixture to 10, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a white solid product (7.5g, 87%).
[0297] 1HNMR (400MHz, DMSO-d6) δ 6.55 (d, J = 8.4 Hz, 1H), 6.52 (d, J = 8.4 Hz, 1H), 4.73 (br, 2H), 4.50 (t, J = 8.4 Hz, 2H), 3.08 (t, J = 8.8 Hz, 2H).
[0298] Step 3: Synthesis of (4-bromo-2,3-dihydrobenzofuran-5-yl)carbamate tert-butyl ester (intermediate 25-3)
[0299] 5-amino-4-bromo-2,3-dihydrobenzofuran (7.8 g, 36.45 mmol) was added to THF (60 ml), followed by the addition of NaHMDS (146 ml, 0.5 M toluene solution) at 0°C and the reaction was carried out with stirring for 1 hour. Subsequently, Boc2O (8.6 g, 40.1 mmol) was added and the reaction was carried out with stirring at 25°C for 12 hours. The solution was then neutralized by adding a saturated aqueous NH4Cl solution and extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow solid product (9.8 g, 82%).
[0300] 1 HNMR (400 MHz, DMSO-d6) δ 8.48 (s, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 4.59 (t, J = 8.4 Hz, 2H), 3.17 (t, J = 8.4 Hz, 2H), 1.43 (s, 9H).
[0301] Step 4: Synthesis of (4-trimethylsilylethynyl-2,3-dihydrobenzofuran-5-yl)carbamate tert-butyl ester (intermediate 25-4)
[0302] (4-bromo-2,3-dihydrobenzofuran-5-yl)carbamate tert-butyl ester (1.8 g, 5.75 mmol), 2-ethynyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (2.6 g, 11.5 mmol), Cs2CO3 (5.6 g, 17.25 mmol), Pd(dppf)Cl2 (417 mg, 0.57 mmol), and Xphos (547 mg, 1.15 mmol) were added to a mixed solvent of 1,4-dioxane (25 ml) and water (2.5 ml). The reaction was carried out for 4 hours in a sealed tube at 110°C under a nitrogen atmosphere. The reaction was treated by adding water, and the mixture was extracted with ethyl acetate. The organic phase was dried and concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a pale yellow liquid product (1.3 g).
[0303] Step 5: Synthesis of 1,6-Dihydro-2H-furo[3,2-e]indole (Intermediate 25-5)
[0304] (4-trimethylsilylethynyl-2,3-dihydrobenzofuran-5-yl)carbamate tert-butyl ester (1.3g) and t-BuOK (880mg, 7.85mmol) were added to NMP (7ml), and the mixture was reacted at 80°C for 1 hour. After cooling to room temperature, a saturated aqueous NH4Cl solution was added to neutralize the reaction mixture, and it was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a pale white solid product (332mg, 2-step yield 36%).
[0305] MS (ESI) calcd for C 10 H9NO: 159.07; found: 160.35 [M+1].
[0306] 1HNMR (400MHz, DMSO-d6) δ 10.94 (s, 1H), 7.30 (t, J = 2.8 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 6.23-6.21 (m, 1H), 4.52 (t, J = 8.4 Hz, 2H), 3.26 (t, J = 8.4 Hz, 2H).
[0307] Step 6: Synthesis of 8-formyl-1,6-dihydro-2H-furo[3,2-e]indole (intermediate 25-6)
[0308] POCl3 (450 mg, 2.94 mmol) and 1,6-dihydro-2H-furo[3,2-e]indole (332 mg, 2.09 mmol) were added to DMF (1.5 ml). After reacting at room temperature for 2 hours, an aqueous NaOH solution (2.0 M) was added to adjust the pH of the reaction mixture to 9 to 12, and the mixture was heated to 70°C and reacted for 1 hour. After cooling to room temperature, the mixture was filtered to obtain a yellow solid product (270 mg, 69%).
[0309] 1 HNMR (400MHz, DMSO-d6) δ 12.04 (s, 1H), 9.78 (s, 1H), 8.20 (s, 1H), 7.21 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 4.53 (t, J = 8.8) Hz, 2H), 3.57 (t, J = 8.8 Hz, 2H).
[0310] Step 7: Synthesis of 8-cyano-1,6-dihydro-2H-furo[3,2-e]indole (intermediate 25-7)
[0311] 8-formyl-1,6-dihydro-2H-furo[3,2-e]indole (270 mg, 1.44 mmol), hydroxylamine hydrochloride (186 mg, 2.90 mmol), and pyridine (456 mg) were added to DMF (3.0 ml). The mixture was then reacted at 80°C for 2 hours. Acetic anhydride (750 mg) was added, and the mixture was reacted for 12 hours. Subsequently, an aqueous NaOH solution (2.0 M) was added at room temperature to adjust the pH of the reaction mixture to 10 to 12, stirred for half an hour, and extracted with dichloromethane. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a brown solid product (180 mg, 67%).
[0312] MS (ESI) calcd for C 11 H8N2O: 184.06; found: 183.45 [M-1].
[0313] 1 HNMR (400MHz, DMSO-d6) δ 12.06 (s, 1H), 8.17 (s, 1H), 7.27 (d, J = 8.8 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 4.61 (t, J = 8.8 Hz, 2H), 3.43 (t, J = 8.4 Hz, 2H).
[0314] Step 8: Synthesis of 4-(8-cyano-1,2-dihydro-6H-furo[3,2-e]indole-6-yl)benzoic acid tert-butyl ester (intermediate 25-8)
[0315] 8-cyano-1,6-dihydro-2H-furo[3,2-e]indole (100 mg, 0.54 mmol), Cs2CO3 (353 mg, 1.09 mmol), and 4-fluorobenzoic acid tert-butyl ester (213 mg, 1.09 mmol) were added to DMAc (1.5 ml). The mixture was reacted at 100°C for 5 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a white solid product (98 mg, 47%).
[0316] MS (ESI) calcd for C 22 H 20 N2O3: 360.15; found: 361.30 [M+1].
[0317] 1 HNMR (400MHz, DMSO-d6) δ 8.61 (s, 1H), 8.10 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 4.68 (t, J = 8.8 Hz, 2H), 3.51 (t, J = 8.8 Hz, 2H), 1.58 (s, 9H).
[0318] Step 9: Synthesis of 4-(8-cyano-1,2-dihydro-6H-furo[3,2-e]indole-6-yl)benzoic acid (Compound 25)
[0319] 4-(8-cyano-1,2-dihydro-6H-furo[3,2-e]indole-6-yl)benzoic acid tert-butyl ester (98 mg, 0.27 mmol) was added to TFA (2 ml). Afterward, the mixture was reacted at room temperature for 1 hour, water was added to process the reaction, and the mixture was filtered. The resulting filter cake was washed with water and dried to obtain a pale white solid target product (64 mg, 77%).
[0320] MS (ESI) calcd for C 18 H12 N2O3: 304.08; found: 305.25 [M+1].
[0321] 1 HNMR (400MHz, DMSO-d6) δ 8.62 (s, 1H), 8.14 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.8 Hz, 2H), 7.42 (d, J = 9.2 Hz, 1H), 6.89 (d, J = 9.2 Hz, 1H), 4.67 (t, J = 8.8 Hz, 2H), 3.51 (t, J = 8.4 Hz, 2H).
[0322] Example 9 Preparation of Compound 61
[0323]
[0324] Step 1: Synthesis of 4-iodo-5-aminoisoindoline-2-carboxylic acid tert-butyl ester (intermediate 61-1)
[0325] 5-aminoisoindoline-2-carboxylic acid tert-butyl ester (5.0 g, 21.35 mmol) and NIS (4.32 g, 19.22 mmol) were added to a mixed solvent of dichloromethane (23 ml) and acetic acid (46 ml), and the mixture was stirred at room temperature for 2 hours. Sodium sulfite solution (1.0 M) was added and the reaction mixture was treated until it turned pale yellow, then sodium carbonate was added to neutralize it, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a yellow solid product (2.7 g, 35%).
[0326] 1 H NMR (400 MHz, CDCl3) δ 7.01-6.93 (m, 1H), 6.67-6.61 (m, 1H), 4.72-4.68 (m, 2H), 4.55-4.48 (m, 2H), 1.53-1.51 (m, 9H).
[0327] Step 2: Synthesis of 4-trimethylsilylethynyl-5-aminoisoindolin-2-carboxylic acid tert-butyl ester (intermediate 61-2)
[0328] 4-iodo-5-aminoisoindoline-2-carboxylic acid tert-butyl ester (2.7g, 9.89 mmol), trimethylsilylacetylene (4.9g, 49.45 mmol), CuI (3.8g, 19.78 mmol), and Pd(dppf)Cl2 (2.2g, 2.97 mmol) were added to triethylamine (34 ml). After reacting at 80°C for 24 hours, the mixture was cooled to room temperature and filtered. The filtrate was concentrated, water was added to the mixture to continue the reaction, and the product was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a brown solid product (2.0g, 61%).
[0329] 1 H NMR (400 MHz, DMSO-d6) δ 7.02-6.98 (m, 1H), 6.63 (d, J=8.4 Hz, 1H), 5.36 (s, 2H), 4.44 (s, 2H), 4.42 (s, 2H), 1.44 (s,9H), 0.24 (s, 9H).
[0330] Step 3: Synthesis of 3,6-Dihydropyrrolo[3,4-e]indole-2(1H)-carboxylic acid tert-butyl ester (Intermediate 61-3)
[0331] 4-trimethylsilylethynyl-5-aminoisoindoline-2-carboxylic acid tert-butyl ester (2.0 g, 6.05 mmol) and CuI (1.73 g, 9.09 mmol) were added to DMF (28 ml). After reacting at 110°C for 2 hours, the mixture was cooled to room temperature, filtered, water was added to continue the reaction, and extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a yellow solid product (784 mg, 50%).
[0332] 1H NMR (400 MHz, DMSO-d6) δ 11.23 (s, 1H), 7.38-7.32 (m, 2H), 7.04-7.01 (m, 1H), 6.40-6.38 (m, 1H), 4.75-4.62 (m, 4H), 1.48-1.47 (m ,9H).
[0333] Step 4: Synthesis of 2-methyl-1,2,3,6-tetrahydropyrrolo[3,4-e]indole (intermediate 61-4)
[0334] 3,6-dihydropyrrolo[3,4-e]indole-2(1H)-carboxylic acid tert-butyl ester (684 mg, 2.65 mmol) and LAH (202 mg) were added to THF (13 ml). After reacting at 60°C for 2 hours, the mixture was cooled to room temperature, and water and sodium hydroxide (4.0 M) were added to continue the reaction. After filtration, the filtrate was concentrated under reduced pressure to remove the solvent, and then purified by column chromatography to obtain a yellow solid product (411 mg, 90%).
[0335] LCMS calcd for C 11 H 12 N2: 172.10; found: 173.35 [M+1].
[0336] 1 H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 7.32-7.31 (m, 1H), 7.22 (d, J=8.4 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 6.28-6.27 (m, 1H), 4.00 (s, 2H), 3.89 (s, 2H), 2.54 (s, 3H).
[0337] Step 5: Synthesis of 8-formyl-2-methyl-1,2,3,6-tetrahydropyrrolo[3,4-e]indole (intermediate 61-5)
[0338] 2-methyl-1,2,3,6-tetrahydropyrrolo[3,4-e]indole (200 mg, 1.16 mmol) and POCl3 (271 mg) were added to DMF (4.0 ml). After reacting at room temperature for 3 hours, an aqueous NaOH solution (4.0 M) was added to adjust the pH of the reaction mixture to 13, and the mixture was heated to 70°C and reacted for 0.5 hours. After cooling to room temperature, the mixture was extracted with ethyl acetate, the organic phase was dried, and the solvent was removed by vacuum concentration. The mixture was then purified by column chromatography to obtain a brown crude product (163 mg).
[0339] LCMS calcd for C 12 H 12 N2O: 200.09; found: 201.30 [M+1].
[0340] Step 6: Synthesis of 8-cyano-2-methyl-1,2,3,6-tetrahydropyrrolo[3,4-e]indole (intermediate 61-6)
[0341] 8-formyl-2-methyl-1,2,3,6-tetrahydropyrrolo[3,4-e]indole (163 mg, 0.82 mmol), hydroxylamine hydrochloride (114 mg, 1.64 mmol), and pyridine (0.4 ml) were added to THF (4 ml). The mixture was then reacted at 80°C for 5 hours. Acetic anhydride (0.7 ml) was added, and the mixture was reacted for 12 hours. Subsequently, an aqueous NaOH solution (4.0 M) was added at room temperature to adjust the pH of the reaction mixture to 10, the mixture was stirred for 0.5 hours, and extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain the product (65 mg, 40%).
[0342] LCMS calcd for C 12 H 11 N3: 197.10; found: 198.35 [M+1].
[0343] Step 7: Synthesis of 4-(8-cyano-2-methyl-2,3-dihydropyrrolo[3,4-e]indole-6(1H)-yl)benzoic acid tert-butyl ester (intermediate 61-7)
[0344] 8-cyano-2-methyl-1,2,3,6-tetrahydropyrrolo[3,4-e]indole (60 mg, 0.3 mmol), Cs2CO3 (195 mg, 0.6 mmol), and 4-fluorobenzoic acid tert-butyl ester (88 mg, 0.45 mmol) were added to DMF (1.5 ml). The mixture was reacted at 80°C for 12 hours, after which it was cooled to room temperature. Water was added to continue the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried, concentrated under reduced pressure to remove the solvent, and purified by column chromatography to obtain a pale white solid product (15 mg, 13%).
[0345] LCMS calcd for C 23 H 23 N3O2: 373.18; found: 374.30 [M+1].
[0346] Step 8: Synthesis of 4-(8-cyano-2-methyl-2,3-dihydropyrrolo[3,4-e]indole-6(1H)-yl)benzoic acid trifluoroacetate (Compound 61)
[0347] 4-(8-cyano-2-methyl-2,3-dihydropyrrolo[3,4-e]indole-6(1H)-yl)benzoic acid tert-butyl ester (15 mg, 0.04 mmol) was added to TFA (0.3 ml). The mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure to remove the solvent, slurried with ethanol, and dried to obtain a pale white solid target product (10 mg, 51%).
[0348] LCMS calcd for C 19 H 15 N3O2: 317.12; found: 318.30 [M+1].
[0349] 1H NMR (400 MHz, DMSO-d6) δ 11.01 (s, 1H), 8.80 (s, 1H), 8.18 (d, J=8 Hz, 2H), 7.81 (d, J=8.4 Hz, 2H), 7.71 (d, J=8.4 Hz, 1H), 7.44 (d, J=8.8 Hz, 1H), 5.06 (s, 2H), 4.75 (s,2H), 3.16 (s, 3H).
[0350] Compounds 1 to 193 were prepared by referring to the preparation methods of Examples 1 to 9, and the examples referenced in their preparation methods, their structural formulas, and characterization data are shown in Table 1.
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358] Example 10 Inhibition of a compound on xanthine oxidase activity
[0359] 3 mg each of the test compound and Febuxostat, a positive control, were taken and dissolved in DMSO to prepare a 10 mM mother liquor, and then serially diluted with a 5% aqueous DMSO solution to prepare eight concentration gradients (500 μM, 50 μM, 5 μM, 500 nM, 250 nM, 50 nM, 5 nM, 0.5 nM) containing the same concentration of DMSO.
[0360] The xanthine oxidase activity detection kit (MAK078-1KT) was purchased from the official website of the reagent supplier, Merck. A tissue homogenate containing mouse xanthine oxidase was obtained by homogenizing mouse liver tissue (500 µl / 30 mg) using the detection buffer of the kit. After centrifugation at 10,000 rpm x 10 min at 4°C for 10 minutes, the supernatant was transferred to a new centrifuge tube, placed on ice, and stored separately.
[0361] 50 µl of tissue homogenate was added to a 96-well plate, 2 µl of the test compound at a corresponding concentration was added, and then 48 µl of the mixture containing other components of the kit was added to make the total volume per well 100 µl. After incubating at 25°C for 3 minutes, the sample was excited at a wavelength of 535 nm, and the fluorescence intensity excited at 587 nm was read (indicating that the higher the amount of superoxide radicals generated by the oxidation of hypoxanthine and xanthine by xanthine oxidase in the reaction system, the greater the amount of resorufin generated by the chemical reaction with 10-acetyl-3,7-dihydroxyphenoxazine in the reaction system, and that higher excited fluorescence intensity indicates higher activity of xanthine oxidase). The fluorescence intensity was dynamically read at 3-minute intervals for 15 minutes at 25°C. The xanthine oxidase activity of wells without inhibitor addition was set to 100%, and the activity of wells without enzyme addition was set to 0% (background value). After plate reading, QC was performed to confirm that the 12-minute time point was within the linear range, and the inhibition efficiency at the 12-minute time point was analyzed to determine the IC50 of the test compound. 50 I obtained the value.
[0362] As shown in Table 2, the test results showed that the indole-fused saturated cyclic compounds of the present invention or their derivatives exhibited a strong inhibitory effect on xanthine oxidase activity, and the inhibitory activity of some compounds was superior to that of febuxostat, a positive control drug.
[0363]
[0364] Example 11 Inhibition of a compound on uric acid transporters
[0365] A concentration gradient of the test compound and the positive control (resinurad) was prepared as in Example 10.
[0366] All cell media were purchased from Invitrogen, and plastic products were purchased from Corning. Since renal tubular epithelial cells express Urat1 and Glut9, these epithelial cells can be used for the detection of uric acid transporter activity. Mouse renal tubular epithelial cells were inoculated onto cell culture transwell membranes with 0.4 µm micropore diameters and cultured until the cells completely covered the transwell to form a monolayer cell membrane. Before detecting the test compound, the inside of the transwell cup was replaced with DMEM basal medium containing a specific concentration of the test compound and 4.5 mg / dL of uric acid. The bottom of the multi-well plate was replaced with DMEM basal medium free of uric acid. After incubation at 37°C for 60 minutes, 100 µl of medium was taken from the bottom of the multi-well plate, and the uric acid concentration was read at 290 nm using a microplate reader. The well without added uric acid was set as a blank control, and the well without added compound was set as 100% transport. The inhibition rate was obtained by comparing the uric acid concentration in the well corresponding to the test compound with the concentration in the 100% transport well.
[0367] According to the results, lesinurad showed an inhibition rate of 23.63% against uric acid transporters at a concentration of 1000 nM, and compound 6 showed an inhibition rate of 64% against uric acid transporters at a concentration of 250 nM. From this, it can be seen that the compounds of the present invention have excellent inhibitory activity against uric acid transporters, and that the inhibitory activity against uric acid transporters at a concentration of 250 nM is higher than that of lesinurad at a concentration of 1000 nM.
[0368] Example 12 Inhibition of a compound on uric acid transporters
[0369] In this example, the inhibitory activity of candidate compounds against human uric acid transporters was measured by commissioning a third-party institution (Beijing Kanglong Huacheng Co., Ltd.) and using HEK-293 cells (HEK293-hURAT1), which stably express an overdose of human uric acid transporters (protein name: URAT1, gene name: SLC22A12), as a cell model for uric acid transport research. A concentration gradient of the test compound and a positive control (resinurad) was prepared as in Example 10. All cell media were purchased from Invitrogen, and plastic products were purchased from Corning. C14-labeled uric acid was purchased from VWR, USA, and the specific procedure is as follows.
[0370] Cells were pre-seeded into a 96-well plate, and the following day, the medium was replaced with a pre-mixed mixture of C14-labeled uric acid and different concentrations of positive control or other test compounds. After incubation for 5 minutes, the medium was removed, the cells were lysed with 0.1N NaOH, and the supernatant was read using a Levitti liquid scintillation counter (model MicroBeta2). By defining the readings from wells without any added compounds as 100% uric acid transport and the readings from wells without added C14-labeled uric acid as background values, the inhibitory efficiency of the uric acid transporter by different concentrations of the positive control or test compounds was calculated to determine the IC50. 50 I obtained.
[0371] As shown in Table 3, the test results indicate that the uric acid transporter inhibitory activity of Compound 6 of the present invention was equivalent to that of the positive control (resinurad) under the same experimental conditions. From this, it can be seen that the compound of the present invention has excellent inhibitory activity against uric acid transporters.
[0372]
[0373] Example 13. Efficacy test of a compound that reduces uric acid in the body
[0374] In this example, 8 to 12-week-old adult male Balb / c mice provided by Vital River were classified into a baseline, a vehicle, and a treatment group (compounds 1 and 6). The baseline group received no treatment. For oral administration, 0.5 mL of a 1.2% aqueous solution of 2-BP-β-CD (cyclodextrin) was administered to the vehicle, and 0.5 mL of a test compound solution prepared with 1.2% 2-BP-β-CD (cyclodextrin) was administered to the treatment group. After 7 hours, hyperuricemia was induced by orally administering 0.5 mL of a mixed solution prepared with 0.5% aqueous methylcellulose containing 60 mg / ml potassium oxonate (an inhibitor of uric acid degrading enzyme) and 6.67 mg / ml hypoxanthine (a substrate of xanthine oxidase). After 1 hour, 100 μL of peripheral blood was taken from the medial wall of the orbit, and serum uric acid concentration was measured using the conventional phosphotungstic acid method.
[0375] As shown in Figure 1, the results showed that compounds 1 and 6 were able to effectively reduce blood uric acid levels by approximately half compared to the control group after 8 hours of administration.
[0376] Each technical feature of the embodiments described above may be combined arbitrarily, and for the sake of brevity, not all possible combinations of each technical feature are described in the following embodiments; however, as long as there is no contradiction in such combinations of technical features, they should all be deemed to fall within the scope described herein.
[0377] The embodiments described above are merely illustrative of various embodiments of the present invention. Although the description is relatively specific and detailed, it should not be understood as limiting the scope of patent protection of the present invention for this reason. A person skilled in the art may make various modifications and changes within the scope of the technical spirit of the present invention, and all such modifications and changes fall within the scope of protection of the present invention. Accordingly, the scope of patent protection of the present invention should be based on the appended claims.
Claims
Claim 1 As an indole fused saturated cyclic compound having a structure represented by formula (I) or formula (II), or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, In the above formula, X is -O-, -S-, -CH2-, -NR 2 Selected from -;Y is -O-, -S-, -NR 2 Selected from; m and n are each independently selected from 0, 1, and 2, and m+n=2; Z and W are each independently CR 3 Selected from; Q is hydrogen, one or more R 4 A C1-C6 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C6 alkoxy group substituted or unsubstituted with , one or more R 4 Selected from C1-C6 alkylthio groups, halogens, cyano groups, aldehyde groups, carboxyl groups, nitro groups, and hydroxyl groups substituted or unsubstituted with; L is hydrogen, and one or more R 4 A C1-C6 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C6 alkoxy group substituted or unsubstituted with , one or more R 4 A C1-C6 alkylthio group substituted or unsubstituted with, a halogen, a cyano group, an aldehyde group, a carboxyl group, a nitro group, a hydroxyl group, one or more R 5 A C3-C8 cycloalkyl group substituted or unsubstituted with, one or more R 5 A 3-8-membered heterocyclic ring substituted or unsubstituted with R, one or more R 6 C6-C substituted or unsubstituted 10 Aryl group, one or more R 6 A 5-10-membered heteroaryl group substituted or unsubstituted with, Selected from;X 1 , X 2 are independently -O-, -S-, -C(R 1 )2-, -NR 2 Selected from -;Z 1 , Z 2 and Z 3 CR each independently 3 , selected from N; each R 1 Each is independently selected from hydrogen, C1-C6 alkyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, and halogens; and each R 2 are each independently selected from hydrogen and C1-C6 alkyl groups; and each R 3 Each is independently selected from hydrogen, C1-C6 alkyl groups, C1-C6 alkoxy groups, C1-C6 alkylthio groups, and halogens; and each R 4 Each is independently selected from hydrogen, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, C3-C8 cycloalkyl group, and 3-8 heterocyclic group; and each R 5 Each is independently selected from hydrogen, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group; and each R 6 Each is independently hydrogen, C1-C6 alkyl group, C1-C6 alkyl group substituted with a halogen, C1-C6 alkyl group substituted with a C1-C6 alkoxy group, C1-C6 alkoxy group, C1-C6 alkoxy group substituted with a C1-C6 alkoxy group, C1-C6 alkylthio group, halogen, cyano group, -C(=O)R, nitro group, hydroxyl group, thiol group, amino group, R 5 An aryl group substituted or unsubstituted with R 5 Selected from 5-10 member heteroaryl groups substituted or unsubstituted with R; each R is independently selected from hydrogen, hydroxyl group, hydroxyamino group, amino group, halogen, C1-C6 alkyl group, C1-C6 alkoxy group, C1-C6 alkylthio group, C1-C6 alkylamine group, indole-fused saturated cyclic compounds or derivatives thereof, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrug molecules thereof, or deuterides thereof, or tritium thereof. Claim 2 In claim 1, the indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, wherein the indole-fused saturated cyclic compound or its derivative has a structure represented by formula (III) or formula (IV): Claim 3 In claim 1, the indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, wherein the indole-fused saturated cyclic compound or its derivative has a structure represented by formula (V-1), formula (V-2), formula (V-3), formula (V-4), formula (V-5), formula (V-6), formula (V-7), or (V-8). Claim 4 In any one of paragraphs 1 to 3, each R 2 is selected from hydrogen and C1-C3 alkyl groups; preferably, each R 2 An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from hydrogen, a methyl group, or an ethyl group. Claim 5 In any one of paragraphs 1 to 3, X 1 , X 2 are independently -O-, -S-, -C(R 1 )2-, -NR 2 Selected from;Z 1 , Z 2 and Z 3 CR each independently 3 , selected from N; each R 1 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, fluorine, chlorine, and bromine; and each R 2 Each is independently selected from hydrogen and C1-C3 alkyl groups; and each R 3 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, and halogens; preferably, X 1 is selected from -O-, -S-, and X 2 is -NR 2 - and, R 2 is selected from hydrogen, methyl group, ethyl group, and propyl group; preferably, Z 1 , Z 2 and Z 3 0 or 1 of them are N, and the rest are all CR 3 is, R 3 An indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, characterized by being selected from hydrogen, methyl, ethyl, and propyl groups. Claim 6 In any one of paragraphs 1 to 3, each R 4 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, halogens, cyano groups, aldehyde groups, carboxyl groups, nitro groups, hydroxyl groups, C3-C6 cycloalkyl groups, and 3-6 heterocyclic groups; and / or, each R 5 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, halogens, cyano groups, aldehyde groups, carboxyl groups, nitro groups, and hydroxyl groups; preferably, each R 4 Each is independently selected from hydrogen, methyl group, ethyl group, propyl group, methoxy group, ethoxy group, propoxy group, methylthio group, ethylthio group, propylthio group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, oxetanyl group, tetrahydrofuranyl group, oxacyclohexyl group, tetrahydropyrrolyl group, tetrahydrothienyl group; preferably, each R 5 An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by each being independently selected from hydrogen, methyl group, ethyl group, propyl group, methoxy group, ethoxy group, propoxy group, methylthio group, ethylthio group, propylthio group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group. Claim 7 In any one of paragraphs 1 to 3, each R 6 Each is independently hydrogen, C1-C3 alkyl group, C1-C3 alkyl group substituted with a halogen, C1-C3 alkyl group substituted with a C1-C3 alkoxy group, C1-C3 alkoxy group, C1-C3 alkoxy group substituted with a C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, -C(=O)R, nitro group, hydroxyl group, thiol group, amino group, R 5 A phenyl group substituted or unsubstituted with R 5 Naphthyl group substituted or unsubstituted with R 5 Selected from a 5-6-membered heteroaryl group substituted or unsubstituted; each R is independently selected from hydrogen, a hydroxyl group, a hydroxyamino group, an amino group, a halogen, a C1-C3 alkyl group, a C1-C3 alkoxy group, or a C1-C3 alkylamine group; preferably, each R 6 Each is independently hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, methoxy group, ethoxy group, propoxy group, methylthio group, ethylthio group, propylthio group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, -C(=O)NHOH, formyl group, acetyl group, methoxycarbonyl group, ethoxycarbonyl group, carbamoyl group, nitro group, hydroxyl group, thiol group, amino group, methyl group substituted with a methoxy group, ethyl group substituted with a methoxy group, propyl group substituted with a methoxy group, methoxy group substituted with a methoxy group, ethoxy group substituted with a methoxy group, propoxy group substituted with a methoxy group, phenyl group, naphthyl group, pyridyl group, pyrazinyl group, pyridazinyl group, pyrimidinyl group, An indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, characterized by being selected from triazolyl, tetrazolyl, furanyl, thienyl, phylrolyl, and imidazolyl groups. Claim 8 In any one of paragraphs 1 to 3, Q is hydrogen, and one or more R 4 A C1-C3 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C3 alkoxy group substituted or unsubstituted with , one or more R 4 An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized in that Q is selected from a substituted or unsubstituted C1-C3 alkylthio group, a halogen, a cyano group, an aldehyde group, a carboxyl group, a nitro group, or a hydroxyl group; preferably, Q is selected from hydrogen, a methyl group, an ethyl group, a propyl group, a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a monofluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, fluorine, chlorine, bromine, iodine, a cyano group, an aldehyde group, a carboxyl group, a nitro group, or a hydroxyl group; preferably, Q is selected from a cyano group, a chlorine group, or a bromine group; and more preferably, Q is a cyano group. Claim 9 In any one of paragraphs 1 to 3, L is hydrogen, and one or more R 4 A C1-C3 alkyl group substituted or unsubstituted with, one or more R 4 A C1-C3 alkoxy group substituted or unsubstituted with , one or more R 4 A C1-C3 alkylthio group substituted or unsubstituted with, a halogen, a cyano group, an aldehyde group, a carboxyl group, a nitro group, a hydroxyl group, one or more R 5 A C3-C6 cycloalkyl group substituted or unsubstituted with, one or more R 5 A 3-6 binary heterocyclic ring substituted or unsubstituted with R, one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A naphthyl group substituted or unsubstituted with, one or more R 6 A 5-6 member heteroaryl group substituted or unsubstituted with, Selected from;X 1 , X 2 are independently -O-, -S-, -C(R 1 )2-, -NR 2 Selected from -;Z 1 , Z 2 and Z 3 CR each independently 3 , selected from N; each R 1 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, and halogens; and each R 2 are each independently selected from hydrogen and C1-C3 alkyl groups; and each R 3 Each is independently selected from hydrogen, C1-C3 alkyl groups, C1-C3 alkoxy groups, C1-C3 alkylthio groups, and halogens; and each R 4 Each is independently selected from hydrogen, C1-C3 alkyl group, C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, C3-C6 cycloalkyl group, 3-6 heterocyclic group; and each R 5 Each is independently selected from hydrogen, C1-C3 alkyl group, C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, aldehyde group, carboxyl group, nitro group, and hydroxyl group; and each R 6 Each is independently hydrogen, C1-C3 alkyl group, C1-C3 alkyl group substituted with a C1-C3 alkoxy group, C1-C3 alkoxy group, C1-C3 alkoxy group substituted with a C1-C3 alkoxy group, C1-C3 alkylthio group, halogen, cyano group, C(=O)R, nitro group, hydroxyl group, thiol group, amino group, R 5 A phenyl group substituted or unsubstituted with R 5 Naphthyl group substituted or unsubstituted with R 5 An indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, characterized in that each R is selected from a 5-6-membered heteroaryl group substituted or unsubstituted with R; and each R is independently selected from hydrogen, a hydroxyl group, a hydroxyamino group, an amino group, a halogen, a C1-C3 alkyl group, a C1-C3 alkoxy group, or a C1-C3 alkylamine group. Claim 10 In paragraph 9, L is hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, monofluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, nitro group, hydroxyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, oxetanyl group, tetrahydrofuranyl group, oxacyclohexyl group, tetrahydropyrrolyl group, tetrahydrothienyl group, tetrahydropyrrolyl group substituted with a halogen, tetrahydropyrrolyl group substituted with a hydroxyl group, azetidinyl group, azetidinyl group substituted with a halogen, azetidinyl group substituted with a hydroxyl group, one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A naphthyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 A pyridazinel group substituted or unsubstituted with, one or more R 6 A pyrimidinyl group substituted or unsubstituted with, Selected from; each R 6 Each is independently hydrogen, methyl group, ethyl group, propyl group, monofluoromethyl group, difluoromethyl group, trifluoromethyl group, methoxy group, ethoxy group, propoxy group, fluorine, chlorine, bromine, iodine, cyano group, aldehyde group, carboxyl group, -C(=O)NHOH, formyl group, acetyl group, methoxycarbonyl group, ethoxycarbonyl group, carbamoyl group, nitro group, hydroxyl group, thiol group, amino group, methyl group substituted with a methoxy group, ethyl group substituted with a methoxy group, propyl group substituted with a methoxy group, methoxy group substituted with a methoxy group, ethoxy group substituted with a methoxy group, propoxy group substituted with a methoxy group, phenyl group, naphthyl group, pyridyl group, pyrazinyl group, pyridazinyl group, pyrimidinyl group, triazolyl group, tetrazolyl group, furanyl group, An indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, characterized by being selected from a thienyl group, a phylrolyl group, or an imidazolyl group. Claim 11 In Clause 10, L is Selected from; preferably, L is An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from. Claim 12 In any one of paragraphs 1 to 3, Q is selected from halogens and cyano groups; and L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Pyridazinyl group substituted or unsubstituted, Selected from; each R 6 An indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, characterized by each being independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, or -C(=O)NHOH. Claim 13 In Clause 12, Q is selected from chlorine, bromine, and cyano groups; and L is An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from. Claim 14 In any one of claims 1 to 3, the indole fusion saturated cyclic compound or its derivative has a structure represented by formula (V-1), Q is a cyano group; L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazine groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH; preferably, L is Selected from; more preferably, L is An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from. Claim 15 In any one of claims 1 to 3, the indole fused saturated cyclic compound or its derivative has a structure represented by formula (V-3), Q is a cyano group; L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazine groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH; preferably, L is Selected from; more preferably, L is An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from. Claim 16 In any one of claims 1 to 3, the indole fusion saturated cyclic compound or its derivative has a structure represented by formula (V-5), Q is a cyano group; L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazine groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH; preferably, L is Selected from; more preferably, L is An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from. Claim 17 In any one of claims 1 to 3, the indole fusion saturated cyclic compound or its derivative has a structure represented by formula (V-1), In the above formula, Q is chlorine or bromine; L is one or more R 6 A phenyl group substituted or unsubstituted with, one or more R 6 A pyridyl group substituted or unsubstituted with, one or more R 6 A pyrazinyl group substituted or unsubstituted with, one or more R 6 Selected from pyridazine groups substituted or unsubstituted with; and each R 6 Each is independently selected from hydrogen, methyl group, ethyl group, carboxyl group, hydroxyl group, tetrazolyl group, and -C(=O)NHOH; preferably, L is Selected from; more preferably, L is An indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, characterized by being selected from. Claim 18 In claim 1, the indole-fused saturated cyclic compound or its derivative is characterized by being selected from the following compounds: an indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium: Claim 19 Application of an indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, according to any one of claims 1 to 18 in the manufacture of XOR inhibitors and / or URAT1 inhibitors. Claim 20 Application of an indole-fused saturated cyclic compound or a derivative thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof, according to any one of claims 1 to 18 in the manufacture of a uric acid-lowering drug. Claim 21 Application of an indole-fused saturated cyclic compound or its derivative, or its stereoisomer, or its pharmaceutically acceptable salt, or its solvate, or its prodrug molecule, or its deuteride, or its tritium, according to any one of claims 1 to 18 in the manufacture of a drug for the prevention and / or treatment of gout or hyperuricemia. Claim 22 XOR / URAT1 dual inhibitor, characterized by containing as an active ingredient an indole-fused saturated cyclic compound or a derivative thereof according to any one of claims 1 to 18, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof. Claim 23 A uric acid-lowering drug, comprising an active ingredient and a pharmaceutically acceptable auxiliary substance, wherein the active ingredient comprises an indole-fused saturated cyclic compound or a derivative thereof according to any one of claims 1 to 18, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof. Claim 24 A method for preventing and / or treating gout or hyperuricemia, comprising the steps of: administering a safe and effective amount of an indole-fused saturated cyclic compound or a derivative thereof according to any one of claims 1 to 18, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug molecule thereof, or a deuteride thereof, or a tritium thereof to a patient with gout or hyperuricemia; and / or administering a safe and effective amount of a uric acid-lowering drug according to claim 23 to a patient with gout or hyperuricemia.
